{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:48:57Z","timestamp":1780109337183,"version":"3.54.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00198-019-05259-1","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T17:02:51Z","timestamp":1576602171000},"page":"827-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of Paget\u2019s disease of bone"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"I.R.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"5259_CR1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0140-6736(68)90236-5","volume":"1","author":"OL Bijvoet","year":"1968","unstructured":"Bijvoet OL, van der Sluys VJ, Jansen AP (1968) Effects of calcitonin on patients with Paget\u2019s disease, thyrotoxicosis, or hypercalcaemia. Lancet 1:876\u2013881","journal-title":"Lancet"},{"key":"5259_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1259\/0007-1285-47-553-1","volume":"47","author":"FH Doyle","year":"1974","unstructured":"Doyle FH, Greenberg PB, Joplin GF et al (1974) Radiological evidence of a dose-related response to long-term treatment of Paget\u2019s disease with human calcitonin. Br J Radiol 47:1\u20138","journal-title":"Br J Radiol"},{"key":"5259_CR3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","volume":"297","author":"R Smith","year":"1971","unstructured":"Smith R, Russell RGG, Bishop M (1971) Diphosphonates and Paget\u2019s disease of bone. Lancet 297:945\u2013947","journal-title":"Lancet"},{"key":"5259_CR4","first-page":"235","volume":"42","author":"R Smith","year":"1973","unstructured":"Smith R, Russell RGG, Bishop MC, Woods CG, Bishop M (1973) Paget\u2019s disease of bone: experience with a diphosphonate (disodium etidronate) in treatment. QJM 42:235\u2013256","journal-title":"QJM"},{"key":"5259_CR5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197312272892601","volume":"289","author":"RD Altman","year":"1973","unstructured":"Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, Sankey RR (1973) Influence of disodium etidronate on clinical and laboratory manifestations of Paget\u2019s disease of bone (osteitis deformans). N Engl J Med 289:1379\u20131384","journal-title":"N Engl J Med"},{"key":"5259_CR6","first-page":"407","volume":"18","author":"FG Kantrowitz","year":"1975","unstructured":"Kantrowitz FG, Byrne MH, Schiller AL et al (1975) Clinical and biochemical effects of diphosphonate in Paget\u2019s disease of bone. Arthritis Rheum 18:407","journal-title":"Arthritis Rheum"},{"key":"5259_CR7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-87-6-656","volume":"87","author":"MRA Khairi","year":"1977","unstructured":"Khairi MRA, Altman RD, De Rosa GP et al (1977) Sodium etidronate in the treatment of Paget\u2019s disease of bone: a study of long term results. Ann Intern Med 87:656\u2013663","journal-title":"Ann Intern Med"},{"key":"5259_CR8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(79)91318-7","volume":"i","author":"WB Frijlink","year":"1979","unstructured":"Frijlink WB, te Velde J, Bijvoet OLM et al (1979) Treatment of Paget\u2019s disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD). Lancet i:799\u2013803","journal-title":"Lancet"},{"key":"5259_CR9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"5259_CR10","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1210\/jc.2014-2910","volume":"99","author":"FR Singer","year":"2014","unstructured":"Singer FR, Bone HG III, Hosking DJ et al (2014) Paget\u2019s disease of bone: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 99:4408\u20134422","journal-title":"J Clin Endocrinol Metab"},{"key":"5259_CR11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jbmr.3873","volume":"34","author":"SH Ralston","year":"2019","unstructured":"Ralston SH, Corral-Gudino L, Cooper C et al (2019) Diagnosis and management of Paget\u2019s disease of bone in adults: a clinical guideline. J Bone Miner Res 34:579\u2013600","journal-title":"J Bone Miner Res"},{"key":"5259_CR12","first-page":"126","volume":"217","author":"BMD Maldague","year":"1987","unstructured":"Maldague BMD, Malghem JMD (1987) Dynamic radiologic patterns of Paget\u2019s disease of Bone. Clin Orthop Relat Res 217:126\u2013151","journal-title":"Clin Orthop Relat Res"},{"key":"5259_CR13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1359\/jbmr.1997.12.4.691","volume":"12","author":"ES Siris","year":"1997","unstructured":"Siris ES, Feldman F (1997) Natural history of untreated Pagets disease of the tibia. J Bone Miner Res 12:691\u2013692","journal-title":"J Bone Miner Res"},{"key":"5259_CR14","first-page":"35","volume":"64","author":"JC Renier","year":"1997","unstructured":"Renier JC, Audran M (1997) Progression in length and width of pagetic lesions, and estimation of age at disease onset. Rev Rhum 64:35\u201343","journal-title":"Rev Rhum"},{"key":"5259_CR15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1148\/radiology.153.3.6494476","volume":"153","author":"CJ Vellenga","year":"1984","unstructured":"Vellenga CJ, Pauwels EK, Bijvoet OL, Frijlink WB, Mulder JD, Hermans J (1984) Untreated Paget disease of bone studied by scintigraphy. Radiology 153:799\u2013805","journal-title":"Radiology"},{"key":"5259_CR16","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S8756-3282(99)00027-7","volume":"24","author":"M Davie","year":"1999","unstructured":"Davie M, Davies M, Francis R, Fraser W, Hosking D, Tansley R (1999) Paget\u2019s disease of bone: a review of 889 patients. Bone 24:11S\u201312S","journal-title":"Bone"},{"key":"5259_CR17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","volume":"17","author":"TP Van Staa","year":"2002","unstructured":"Van Staa TP, Selby P, Leufkens HGM et al (2002) Incidence and natural history of Paget\u2019s disease of bone in England and Wales. J Bone Miner Res 17:465\u2013471","journal-title":"J Bone Miner Res"},{"key":"5259_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-006-0184-2","volume":"80","author":"AL Langston","year":"2007","unstructured":"Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH (2007) Clinical determinants of quality of life in Paget\u2019s disease of bone. Calcif Tissue Int 80:1\u20139","journal-title":"Calcif Tissue Int"},{"key":"5259_CR19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MAO.0b013e318241c3bd","volume":"33","author":"PA Dimitriadis","year":"2012","unstructured":"Dimitriadis PA, Bamiou DE, Bibas AG (2012) Hearing loss in Paget\u2019s disease: a temporal bone histopathology study. Otol Neurotol 33:142\u2013146","journal-title":"Otol Neurotol"},{"key":"5259_CR20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MAO.0000000000001430","volume":"38","author":"NL Deep","year":"2017","unstructured":"Deep NL, Besch-Stokes JG, Lane JI, Driscoll CLW, Carlson ML (2017) Paget\u2019s disease of the temporal bone: a single-institution contemporary review of 27 patients. Otol Neurotol 38:907\u2013915","journal-title":"Otol Neurotol"},{"key":"5259_CR21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","volume":"295","author":"HIJ Harinck","year":"1987","unstructured":"Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL (1987) Paget\u2019s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 295:1301\u20131305","journal-title":"BMJ"},{"key":"5259_CR22","first-page":"79","volume":"217","author":"HIJ Harinck","year":"1987","unstructured":"Harinck HIJ, Bijvoet OLM, Blanksma HJ et al (1987) Efficacious management with aminobisphosphonate (APD) in Paget\u2019s disease of bone. Clin Orthop 217:79\u201398","journal-title":"Clin Orthop"},{"key":"5259_CR23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1259\/0007-1285-60-717-849","volume":"60","author":"GW Dodd","year":"1987","unstructured":"Dodd GW, Ibbertson HK, Fraser TRC, Holdaway IM, Wattie D (1987) Radiological assessment of Paget\u2019s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol 60:849\u2013860","journal-title":"Br J Radiol"},{"key":"5259_CR24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2265.1991.tb00294.x","volume":"34","author":"AJ Fenton","year":"1991","unstructured":"Fenton AJ, Gutteridge DH, Kent GN, Price RI, Retallack RW, Bhagat CI, Worth GK, Thompson RI, Watson IG, Barry-Walsh C (1991) Intravenous aminobisphosphonate in Paget\u2019s disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol 34:197\u2013204","journal-title":"Clin Endocrinol"},{"key":"5259_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S8756-3282(96)00224-4","volume":"19","author":"DH Gutteridge","year":"1996","unstructured":"Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, Stewart GO, Prince RL, Kent GN, Bhagat CI, Price RI, Thompson RI, Nicholson GC (1996) Clinical, biochemical, hematologic, and radiographic responses in Pagets disease following intravenous pamidronate disodium - a 2-year study. Bone 19:387\u2013394","journal-title":"Bone"},{"key":"5259_CR26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/art.1780231018","volume":"23","author":"OLM Bijvoet","year":"1980","unstructured":"Bijvoet OLM, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paassen H, Reitsma PH, te Velde J, de Vries E, van der Wey J (1980) APD in Paget\u2019s disease of bone. Arthritis Rheum 23:1193\u20131204","journal-title":"Arthritis Rheum"},{"key":"5259_CR27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1259\/0007-1285-58-696-1165","volume":"58","author":"CJLR Vellenga","year":"1985","unstructured":"Vellenga CJLR, Pauwels EKJ, Bijvoet OLM, Harinck HI, Frijlink WB (1985) Quantitative bone scintigraphy in Paget\u2019s disease treated with APD. Br J Radiol 58:1165\u20131172","journal-title":"Br J Radiol"},{"key":"5259_CR28","first-page":"961","volume":"81","author":"E Siris","year":"1996","unstructured":"Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M (1996) Comparative study of alendronate versus etidronate for the treatment of Paget\u2019s disease of bone. J Clin Endocrinol Metab 81:961\u2013967","journal-title":"J Clin Endocrinol Metab"},{"key":"5259_CR29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9343(96)00227-6","volume":"101","author":"IR Reid","year":"1996","unstructured":"Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ (1996) Biochemical and radiologic improvement in Paget\u2019s disease of bone treated with alendronate - a randomized, placebo-controlled trial. Am J Med 101:341\u2013348","journal-title":"Am J Med"},{"key":"5259_CR30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","volume":"106","author":"PD Miller","year":"1999","unstructured":"Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Am J Med 106:513\u2013520","journal-title":"Am J Med"},{"key":"5259_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","volume":"22","author":"DJ Hosking","year":"1998","unstructured":"Hosking DJ, Eusebio RA, Chines AA (1998) Pagets-disease of bone - reduction of disease activity with oral risedronate. Bone 22:51\u201355","journal-title":"Bone"},{"key":"5259_CR32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","volume":"13","author":"ES Siris","year":"1998","unstructured":"Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung M, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ (1998) Risedronate in the treatment of Pagets-disease of bone - an open label, multicenter study. J Bone Miner Res 13:1032\u20131038","journal-title":"J Bone Miner Res"},{"key":"5259_CR33","first-page":"1906","volume":"83","author":"FR Singer","year":"1998","unstructured":"Singer FR, Clemens TL, Eusebio RA, Bekker PJ (1998) Risedronate, a highly effective oral agent in the treatment of patients with severe Pagets-disease. J Clin Endocrinol Metab 83:1906\u20131910","journal-title":"J Clin Endocrinol Metab"},{"key":"5259_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S8756-3282(99)00271-9","volume":"26","author":"JP Brown","year":"2000","unstructured":"Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW (2000) Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 26:263\u2013267","journal-title":"Bone"},{"key":"5259_CR35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00223-016-0214-7","volume":"100","author":"IR Reid","year":"2017","unstructured":"Reid IR, Wattie D, Gamble GD et al (2017) Long-term effects of intravenous ibandronate in Paget\u2019s disease of bone. Calcif Tissue Int 100:250\u2013254","journal-title":"Calcif Tissue Int"},{"key":"5259_CR36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","volume":"35","author":"IR Reid","year":"2004","unstructured":"Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35:224\u2013230","journal-title":"Bone"},{"key":"5259_CR37","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","volume":"26","author":"IR Reid","year":"2011","unstructured":"Reid IR, Lyles K, Su GQ, Brown JP, Walsh JP, del Pino-Montes J, Miller PD, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ (2011) A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res 26:2261\u20132270","journal-title":"J Bone Miner Res"},{"key":"5259_CR38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.3029","volume":"32","author":"T Cundy","year":"2017","unstructured":"Cundy T, Maslowski K, Grey A, Reid IR (2017) Durability of response to zoledronate treatment and competing mortality in Paget\u2019s disease of bone. J Bone Miner Res 32:753\u2013756","journal-title":"J Bone Miner Res"},{"key":"5259_CR39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00223-013-9812-9","volume":"94","author":"JP Devogelaer","year":"2014","unstructured":"Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, Macdonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S (2014) Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid. Calcif Tissue Int 94:311\u2013318","journal-title":"Calcif Tissue Int"},{"key":"5259_CR40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00296-010-1648-2","volume":"32","author":"GRW de Castro","year":"2012","unstructured":"de Castro GRW, Heiden GI, Zimmermann AF et al (2012) Paget\u2019s disease of bone: analysis of 134 cases from an island in southern Brazil: another cluster of Paget\u2019s disease of bone in South America. Rheumatol Int 32:627\u2013631","journal-title":"Rheumatol Int"},{"key":"5259_CR41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-017-0261-8","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Maslowski K (2017) Long-term bone scintigraphy results after intravenous zoledronate in Paget\u2019s disease of Bone. Calcif Tissue Int 101:43\u201349","journal-title":"Calcif Tissue Int"},{"key":"5259_CR42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijem.IJEM_327_18","volume":"23","author":"H Durgia","year":"2019","unstructured":"Durgia H, Sahoo J, Kamalanathan S, Palui R, Kumar R, Halanaik D, Ananthakrishnan R, Sankar G, Sridharan K, Raj H (2019) Response to zoledronic acid in patients with active Paget\u2019s disease of bone: a retrospective study. Indian J Endocrinol Metab 23:117\u2013121","journal-title":"Indian J Endocrinol Metab"},{"key":"5259_CR43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-008-0852-6","volume":"26","author":"A Avramidis","year":"2008","unstructured":"Avramidis A, Polyzos SA, Moralidis E et al (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget\u2019s disease of bone. J Bone Miner Metab 26:635\u2013641","journal-title":"J Bone Miner Metab"},{"key":"5259_CR44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/bonekey.2013.1176","volume":"2","author":"IR Reid","year":"2013","unstructured":"Reid IR, Brown JP, Levitt N et al (2013) Re-treatment of relapsed Paget\u2019s disease of bone with zoledronic acid - results from an open-label study. Bonekey Rep 2:442. https:\/\/doi.org\/10.1038\/bonekey.2013.1176","journal-title":"Bonekey Rep"},{"key":"5259_CR45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1359\/jbmr.090709","volume":"25","author":"AL Langston","year":"2010","unstructured":"Langston AL, Campbell MK, Fraser WD, MacLennan G, Selby PL, Ralston SH, PRISM Trial Group (2010) Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 25:20\u201331","journal-title":"J Bone Miner Res"},{"key":"5259_CR46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bone.2013.04.024","volume":"55","author":"L Corral-Gudino","year":"2013","unstructured":"Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J et al (2013) Epidemiology of Paget\u2019s disease of bone: a systematic review and meta-analysis of secular changes. Bone 55:347\u2013352","journal-title":"Bone"},{"key":"5259_CR47","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/archinte.1995.00430160167017","volume":"155","author":"E Wallace","year":"1995","unstructured":"Wallace E, Wong JC, Reid IR (1995) Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Int Med 155:1813\u20131815","journal-title":"Arch Int Med"},{"key":"5259_CR48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1302\/0301-620X.63B4.6457839","volume":"63-B","author":"DL Douglas","year":"1981","unstructured":"Douglas DL, Duckworth T, Kanis JA et al (1981) Spinal cord dysfunction in Paget\u2019s disease of bone. J Bone Joint Surg 63-B:495\u2013502","journal-title":"J Bone Joint Surg"},{"key":"5259_CR49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0140-6736(82)91411-8","volume":"1","author":"S Charhon","year":"1982","unstructured":"Charhon S, Chapuy MC, Valentin-Opran A, Meunier PJ (1982) Intravenous etidronate for spinal cord dysfunction due to Paget\u2019s disease. Lancet 1:391\u2013392","journal-title":"Lancet"},{"key":"5259_CR50","first-page":"448","volume":"29","author":"J-R Chen","year":"1979","unstructured":"Chen J-R, Rhee RSC, Wallach S et al (1979) Neurologic disturbances in Paget disease of bone: response to calcitonin. J Neurol 29:448\u2013457","journal-title":"J Neurol"},{"key":"5259_CR51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00007632-197905000-00007","volume":"4","author":"LA Walpin","year":"1979","unstructured":"Walpin LA, Singer FR (1979) Paget\u2019s disease. Reversal of severe paraparesis using calcitonin. Spine 4:213\u2013219","journal-title":"Spine"},{"key":"5259_CR52","first-page":"715","volume":"23","author":"WR Smidt","year":"1994","unstructured":"Smidt WR, Hadjipavlou AG, Lander P, Dzioba RB (1994) An algorithmic approach to the treatment of Paget\u2019s disease of the spine. Orthop Rev 23:715\u2013724","journal-title":"Orthop Rev"},{"key":"5259_CR53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3171\/jns.1972.37.6.0661","volume":"37","author":"ES Sadar","year":"1972","unstructured":"Sadar ES, Walton RJ, Gossman HH (1972) Neurological dysfunction in Paget\u2019s disease of the vertebral column. J Neurosurg 37:661\u2013665","journal-title":"J Neurosurg"},{"key":"5259_CR54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00590-015-1659-5","volume":"26","author":"A Jorge-Mora","year":"2016","unstructured":"Jorge-Mora A, Amhaz-Escanlar S, Lois-Iglesias A, Leborans-Eiris S, Pino-Minguez J (2016) Surgical treatment in spine Paget\u2019s disease: a systematic review. Eur J Orthop Surg Traumatol 26:27\u201330","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"5259_CR55","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s005860100329","volume":"10","author":"AG Hadjipavlou","year":"2001","unstructured":"Hadjipavlou AG, Gaitanis IN, Katonis PG et al (2001) Paget\u2019s disease of the spine and its management. Eur Spine J 10:370\u2013384","journal-title":"Eur Spine J"},{"key":"5259_CR56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2106\/00004623-198466050-00015","volume":"66","author":"RL Merkow","year":"1984","unstructured":"Merkow RL, Pellicci PM, Hely DP et al (1984) Total hip replacement for Paget\u2019s disease of the hip. J Bone Joint Surg 66:752\u2013758","journal-title":"J Bone Joint Surg"},{"key":"5259_CR57","doi-asserted-by":"crossref","unstructured":"Parvizi J, Schall DM, Lewallen DG et al (2002) Outcome of uncemented hip arthroplasty components in patients with Paget\u2019s disease. Clin Orthop Relat Res:127\u2013134","DOI":"10.1097\/00003086-200210000-00020"},{"key":"5259_CR58","doi-asserted-by":"crossref","unstructured":"Lewallen DG (1999) Hip arthroplasty in patients with Paget\u2019s disease. Clin Orthop Relat Res:243\u2013250","DOI":"10.1097\/00003086-199912000-00025"},{"issue":"suppl 2","key":"5259_CR59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1359\/jbmr.06s214","volume":"21","author":"J Parvizi","year":"2006","unstructured":"Parvizi J, Klein GR, Sim FHAFNPJ et al (2006) Surgical management of Paget\u2019s disease of bone. J Bone Mineral Res 21(suppl 2):75\u201382","journal-title":"J Bone Mineral Res"},{"key":"5259_CR60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2106\/00004623-199402000-00017","volume":"76","author":"DS Marr","year":"1994","unstructured":"Marr DS, Rosenthal DI, Cohen GL et al (1994) Rapid postoperative osteolysis in Paget disease. A case report. J Bone Joint Surg 76:274\u2013277","journal-title":"J Bone Joint Surg"},{"key":"5259_CR61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.12809\/hkjr1414260","volume":"18","author":"WK Tsang","year":"2015","unstructured":"Tsang WK, Yuen MK (2015) Post-traumatic postoperative osteolysis: an under-recognised cause of recrudescence of osteolysis in quiescent osteoblastic pagetic bone. Hong Kong J Radiol 18:41\u201345","journal-title":"Hong Kong J Radiol"},{"key":"5259_CR62","first-page":"241","volume":"7","author":"M el Sammaa","year":"1986","unstructured":"el Sammaa M, Linthicum FHJ, House HP et al (1986) Calcitonin as treatment for hearing loss in Paget\u2019s disease. Am J Otol 7:241\u2013243","journal-title":"Am J Otol"},{"key":"5259_CR63","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.5650100318","volume":"10","author":"L Alvarez","year":"1995","unstructured":"Alvarez L, Guanabens N, Peris P et al (1995) Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 10:458\u2013465","journal-title":"J Bone Miner Res"},{"key":"5259_CR64","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2019.9751","volume":"322","author":"B Djulbegovic","year":"2019","unstructured":"Djulbegovic B, Guyatt G (2019) Evidence vs consensus in clinical practice guidelines. JAMA 322:725\u2013726","journal-title":"JAMA"},{"key":"5259_CR65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJM199702203360807","volume":"336","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Meunier PJ (1997) The management of Paget\u2019s disease of bone. N Engl J Med 336:558\u2013566","journal-title":"N Engl J Med"},{"key":"5259_CR66","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1359\/jbmr.2001.16.8.1379","volume":"16","author":"KW Lyles","year":"2001","unstructured":"Lyles KW, Siris ES, Singer FR, Meunier PJ (2001) A clinical approach to diagnosis and management of Paget\u2019s disease of bone. J Bone Miner Res 16:1379\u20131387","journal-title":"J Bone Miner Res"},{"key":"5259_CR67","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00223-016-0150-6","volume":"99","author":"IR Reid","year":"2016","unstructured":"Reid IR, Sharma S, Kalluru R, Eagleton C (2016) Treatment of Paget\u2019s disease of bone with denosumab: case report and literature review. Calcif Tissue Int 99:322\u2013325","journal-title":"Calcif Tissue Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05259-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05259-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05259-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:56:21Z","timestamp":1608080181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05259-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5259"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05259-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"3 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}